Scarica l'app Stockscreener
18.96
2.54%
0.47
Dopo l'orario di chiusura:
18.69
-0.27
-1.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - TradingView
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option - GlobeNewswire Inc.
X-Chem Announces Phase 3 Milestone In Collaboration With Relay Therapeutics - TradingView
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics - Yahoo Finance
Relay Therapeutics stock holds near its Nasdaq quote - AD HOC NEWS
Brenton Mar: Reflecting on Transformative Journey in Cancer Drug Development at Relay Therapeutics - Oncodaily
Relay Therapeutics stock consolidates after recent gains as investors watch pipeline progress - AD HOC NEWS
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Unpacking a Potential 41% Upside in the Biotech Sector - DirectorsTalk Interviews
Relay Therapeutics at Morgan Stanley conference: multiple shots on goal By Investing.com - Investing.com Australia
Relay Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Why Is RLAY Stock Rising Today? - Stocktwits
Relay Therapeutics CEO Sanjiv Patel sells 48,199 shares for $912,889.06 - Bitget
Relay Therapeutics (RLAY) Insider Sell: President, R&D Donald Be - GuruFocus
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics R&D president sells $161,814 in stock - investing.com
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) R&D chief sells stock under 10b5-1 plan - Stock Titan
Relay Therapeutics (RLAY) CFO sells about $335K in stock under preset plan - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) CEO sells shares under preset trading plan - Stock Titan
Relay Therapeutics at Wells Fargo conference: pipeline nears key tests By Investing.com - Investing.com Canada
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - news.futunn.com
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
Relay Therapeutics CFO Sells 17,717 Shares for $350,000 - Yahoo Finance
Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats - Quiver Quantitative
Relay Therapeutics management will join two live online talks this month - Stock Titan
Relay Therapeutics (RLAY) Insider Peter Rahmer Sells 4,508 Shares - GuruFocus
Relay Therapeutics (RLAY) exec sells 4,508 shares under plan - Stock Titan
SoftBank Vision Fund Subsidiary Sells 6 Million Shares of Relay Therapeutics at $19.4 Each - Kalkine Media
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m By Investing.com - Investing.com Canada
Relay Therapeutics (NASDAQ: RLAY) 10% owner SoftBank sells 6M shares - Stock Titan
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m - Investing.com
Relay Therapeutics (NASDAQ: RLAY) officer eyes another stock sale after June trade - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) holder plans sale of up to 6M shares - Stock Titan
What is HC Wainwright's Estimate for RLAY FY2027 Earnings? - MarketBeat
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target to $29 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE - MarketBeat
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified? - Yahoo Finance
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade - Stock Titan
Relay Therapeutics (RLAY) CFO sells shares via preset trading plan - Stock Titan
Relay (RLAY) Earnings Metrics: EPS Does Not Reach the Reported Estimate in Latest Trading - Vinanet
Relay Therapeutics stock hits 52-week high at 20.83 USD By Investing.com - Investing.com Canada
Relay Therapeutics stock hits 52-week high at 20.83 USD - Investing.com
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Alphabet Inc. Makes New Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Persistent Asset Partners Ltd Makes New $1.32 Million Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Elmind Capital, LP's Relay Therapeutics Inc(RLAY) Holding History - GuruFocus
Relay Therapeutics (RLAY) Slips 0.35% as Shares Trade Near Midpoint of Key RangeMerger Arbitrage - careplusvn.com
Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) St - GuruFocus
Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position - Stock Titan
J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $31 - Moomoo
RLAY Maintained by JP Morgan -- Price Target Raised to $31.00 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):